US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kurv Yield Premium Strategy Tesla (TSLA) ETF

20.70

-0.1900-0.91%

Post-market: 20.700.00000.00%19:09 EDT

Volume:17.79K

Turnover:367.63K

Market Cap:23.39M

PE:- -

High:20.83

Open:20.79

Low:20.29

Close:20.89

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Upstream Bio announces presentation of data on verekitug’s TSLP receptor

Press Release: Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TSLP"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TSLP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TSLP\",,,,,undefined,":{"symbol":"TSLP","market":"US","secType":"STK","nameCN":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","latestPrice":20.7,"timestamp":1751054400000,"preClose":20.89,"halted":0,"volume":17791,"hourTrading":{"tag":"盘后","latestPrice":20.7,"preClose":20.7,"latestTime":"19:09 EDT","volume":160,"amount":3275.4,"timestamp":1751065787399},"delay":0,"floatShares":1130000,"shares":1130000,"eps":0,"marketStatus":"Market Closed","change":-0.19,"latestTime":"06-27 16:00:00 EDT","open":20.79,"high":20.8287,"low":20.2852,"amount":367625.146886,"amplitude":0.026017,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"exchange":"AMEX","adjPreClose":20.89,"sharesOutstanding":1130000,"nav":20.79,"aum":23492700,"dividendRate":0.43285,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":20.68,"preClose":20.865,"latestTime":"08:21 EDT","volume":11,"amount":228.34999,"timestamp":1751026910552},"postHourTrading":{"tag":"盘后","latestPrice":20.7,"preClose":20.7,"latestTime":"19:09 EDT","volume":160,"amount":3275.4,"timestamp":1751065787399},"volumeRatio":0.5966930511112778,"impliedVol":0.4182,"impliedVolPercentile":0.792},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TSLP\",,,,,undefined,":{"symbol":"TSLP","floatShares":1130000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.5966930511112778,"shares":1130000,"dividePrice":8.96,"high":20.8287,"amplitude":0.026017,"preClose":20.89,"low":20.2852,"week52Low":15.36,"pbRate":"--","week52High":34.2895,"institutionHeld":0,"latestPrice":20.7,"eps":0,"divideRate":0.43285,"volume":17791,"delay":0,"ttmEps":0,"open":20.79,"prevYearClose":30.27,"prevWeekClose":20.53,"prevMonthClose":22.0992,"prevQuarterClose":18.48,"fiveDayClose":20.53,"twentyDayClose":22.584,"sixtyDayClose":19.14},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/TSLP\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TSLP\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2543617943","title":"Upstream Bio announces presentation of data on verekitug’s TSLP receptor","url":"https://stock-news.laohu8.com/highlight/detail?id=2543617943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543617943?lang=en_us&edition=fundamental","pubTime":"2025-06-16 08:30","pubTimestamp":1750033816,"startTime":"0","endTime":"0","summary":"Upstream Bio (UPB) announced the presentation of translational pharmacology modeling data supporting verekitug’s Thymic Stromal Lymphopoietin, TSLP...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/upstream-bio-announces-presentation-of-data-on-verekitugs-tslp-receptor-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/upstream-bio-announces-presentation-of-data-on-verekitugs-tslp-receptor-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UPB","BK4139","TSLP"],"gpt_icon":0},{"id":"2534241948","title":"Press Release: Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2534241948","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534241948?lang=en_us&edition=fundamental","pubTime":"2025-05-12 18:05","pubTimestamp":1747044300,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results. Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling. First patient dosed in Phase 1b trial of APG777 in mild-to-moderate asthma with readout expected in 1H 2026. APG279 on track to initiate Phase 1b head-to-head trial vs DUPIXENT in 2025 with readout expected in 2H 2026. Positive interim Phase 1b readout of APG808 in patients with mild-to-moderate asthma demonstrated rapid, robust and sustained suppression of FeNO, a biomarker of Type 2 inflammation that is associated with exacerbations in asthma. $681.4 million cash, cash equivalents and marketable securities supports runway into Q1 2028. Apogee conducted third-party quantitative market research in April","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","TSLP","BK4097","BK4218","BK4139","PRGS","PK","APGE","LU2065732104.USD"],"gpt_icon":0},{"id":"2532683802","title":"AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2532683802","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532683802?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:01","pubTimestamp":1746129660,"startTime":"0","endTime":"0","summary":"THOUSAND OAKS, Calif., May 1, 2025 /PRNewswire/ -- Amgen  today announced financial results for the first quarter of 2025.\"Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects,\" said Robert A. Bradway, chairman and chief executive officer.For the first quarter, total revenues increased 9% to $8.1 billion in comparison to the first quarter of 2024.Product sales grew 11%, primarily driven by 14% volume growth, partially offset by 6% lower net selling price. U.S. sales grew 14%.Fourteen products delivered at least double-digit sales growth in the first quarter, includingRepatha , BLINCYTO , TEZSPIRE , EVENITY , TAVNEOS  and UPLIZNA .Non-GAAP EPS increased 24% from $3.96 to $4.90, driven by higher revenues, partially offset by higher operating expenses.Repatha  sales increased 27% year-over-year to $656 million in the first quarter, pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2025-200100246.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2025-200100246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4188","LU1983299246.USD","IE0009355771.USD","IE00B4R5TH58.HKD","TSLP","MTA","IE00BJT1NW94.SGD","LU0289739699.SGD","LU0889565916.HKD","IE0002141913.USD","LU0868494617.USD","TCI","BK4585","SLE","AMGN","LU2112291526.USD","LU1023059063.AUD","BK4205","MPA","IE00B2B36J28.USD","BK4160","LU2242646821.SGD","LU0122379950.USD","FCF","LU0058720904.USD","TCS","GIPR","BK4077","LU2468319806.SGD","BK4211","BK4200","BK4139","SG9999001440.SGD","LU2242652126.USD","BK4599","BK4566","BK4096","IE00BFTCPJ56.SGD","PN","BK4534","LU1061106388.HKD","LU1057294990.SGD","BK4533","LU2089984988.USD","BK4588","BK4581","LU0109394709.USD","LU0320765992.SGD","BK4233"],"gpt_icon":0},{"id":"2529637228","title":"Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2529637228","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529637228?lang=en_us&edition=fundamental","pubTime":"2025-04-22 18:59","pubTimestamp":1745319540,"startTime":"0","endTime":"0","summary":"- Initiation of Upcoming Phase 1a/1b Clinical Trial Expected in the Second Quarter of 2025 -. WAYNE, Pa, April 22, 2025  -- Aclaris Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration  has cleared its Investigational New Drug  application for a Phase 1a/1b clinical trial of ATI-052, a potential best-in-class bispecific anti-TSLP/IL-4R monoclonal antibody.ATI-052 is an investigational, potential best-in-class anti-TSLP/IL-4R bispecific monoclonal antibody being developed to treat certain immuno-inflammatory diseases. ATI-052 targets thymic stromal lymphopoietin  and interleukin-4 receptor  that blocks both the upstream TSLP receptor signal transduction and downstream IL-4R activation which inhibits both IL-4 and IL-13 signaling, thereby inhibiting this central proinflammatory pathway and potentially offering enhanced efficacy through dua","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aclaris-therapeutics-secures-u-food-105900381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACRS","LU1878469433.USD","IE00B19Z4B17.USD","TSLP","ATI","LU2065731478.USD","BK4007","IE0031619046.USD","BK4006","IE00B66KJ199.SGD","IE00B7SZL793.SGD"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TSLP\",params:#limit:5,,,undefined,":[{"date":"2025-06-04","symbol":"TSLP","amount":0.5,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-04","defaultRemindTime":1749043800000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-05","payableDate":"2025-06-04","currency":"USD","dateTimestamp":1749009600000,"payDate":"2025-06-05"},{"date":"2025-05-07","symbol":"TSLP","amount":0.55,"announcedDate":"2025-05-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-07","defaultRemindTime":1746624600000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-08","payableDate":"2025-05-07","currency":"USD","dateTimestamp":1746590400000,"payDate":"2025-05-08"},{"date":"2025-04-02","symbol":"TSLP","amount":0.55,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-02","defaultRemindTime":1743600600000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-03","payableDate":"2025-04-02","currency":"USD","dateTimestamp":1743566400000,"payDate":"2025-04-03"},{"date":"2025-03-05","symbol":"TSLP","amount":0.7,"announcedDate":"2025-03-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-05","defaultRemindTime":1741185000000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-06","payableDate":"2025-03-05","currency":"USD","dateTimestamp":1741150800000,"payDate":"2025-03-06"},{"date":"2025-02-05","symbol":"TSLP","amount":1,"announcedDate":"2025-02-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-05","defaultRemindTime":1738765800000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-06","payableDate":"2025-02-05","currency":"USD","dateTimestamp":1738731600000,"payDate":"2025-02-06"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TSLP\",market:\"US\",,,undefined,":[{"executeDate":"2023-11-22","recordDate":"2023-11-24","paymentDate":"2023-11-27","value":0.5775,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-22","value":0.6664,"currency":"USD"},{"executeDate":"2024-01-24","recordDate":"2024-01-25","paymentDate":"2024-01-26","value":0.5555,"currency":"USD"},{"executeDate":"2024-02-21","recordDate":"2024-02-22","paymentDate":"2024-02-23","value":0.313,"currency":"USD"},{"executeDate":"2024-03-20","recordDate":"2024-03-21","paymentDate":"2024-03-22","value":0.5189,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TSLP\",market:\"US\",delay:false,,,undefined,":{}}}